Mark S. Wainwright
Children's Memorial Hospital
25 Papers
96 Citations
Mark S. Wainwright is an academic researcher from Children's Memorial Hospital. The author has contributed to research in topics: Medicine & Neurointensive care. The author has an hindex of 14, co-authored 25 publications.
Chat about Author
Papers
Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents-Second Edition Author Affiliations
Patrick M. Kochanek,P. David Adelson,Stephen Ashwal,Michael J. Bell,Susan L. Bratton,Susan Carson,Randall M. Chesnut,Jamshid Ghajar,Brahm Goldstein,Gerald A. Grant,Niranjan Kissoon,Kimberly Peterson,Nathan R. Selden,Robert C. Tasker,Karen A. Tong,Monica S. Vavilala,Mark S. Wainwright,Craig H Warden,Cynthia Davis-O,Amy Huddleston +19 more
- 01 Jan 2012
TL;DR: This review highlights the need to understand more fully the rationale behind the rapid decline in response to certain types of head injuries in children with severe brain injuries.
360
Acute care clinical indicators associated with discharge outcomes in children with severe traumatic brain injury.
Monica S. Vavilala,Mary A. Kernic,Jin Wang,Nithya Kannan,Richard Mink,Mark S. Wainwright,Jonathan I. Groner,Michael J. Bell,Christopher C. Giza,Douglas F. Zatzick,Richard G. Ellenbogen,Linda Ng Boyle,Pamela H. Mitchell,Frederick P. Rivara +13 more
TL;DR: Acute care clinical indicators of adherence to the Pediatric Guidelines were associated with significantly higher discharge survival and improved discharge Glasgow Outcome Scale, suggesting the need for an interdisciplinary approach to the care of children with severe traumatic brain injury.
Brexanolone as adjunctive therapy in super‐refractory status epilepticus
Eric Rosenthal,Jan Claassen,Mark S. Wainwright,Aatif M. Husain,Henrikas Vaitkevicius,Shane Raines,Ethan Hoffmann,Helen Colquhoun,James J. Doherty,Stephen Kanes +9 more
TL;DR: A multicenter, phase 1/2 study in SRSE patients to evaluate the safety and tolerability of brexanolone (USAN; formerly SAGE‐547 Injection), a proprietary, aqueous formulation of the neuroactive steroid, allopregnanolone.
90
Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia.
Mark S. Wainwright,Jeffrey M. Craft,W. Sue T. Griffin,Alexander Marks,Jose A. Pineda,Kyle R. Padgett,Linda J. Van Eldik +6 more
TL;DR: Measurement of glial fibrillary acidic protein and S100B levels showed a significant increase in the Tg mice, consistent with heightened glial activation and neuroinflammation in response to injury, the first demonstration to the authors' knowledge that overexpression of S 100B in vivo enhances pathological response to Injury.
82
Differences in medical therapy goals for children with severe traumatic brain injury-an international study.
Michael J. Bell,P. David Adelson,James S. Hutchison,Patrick M. Kochanek,Robert C. Tasker,Monica S. Vavilala,Sue R. Beers,Anthony Fabio,Sheryl F. Kelsey,Stephen R. Wisniewski,Laura Loftis,Kevin Morris,Kerri L. LaRovere,Philippe Meyer,Karen Walson,Jennifer Exo,Ajit A. Sarnaik,Todd J. Kilbaugh,Darryl K. Miles,Mark S. Wainwright,Nathan P. Dean,Ranjit S. Chima,Katherine Biagas,Mark J. Peters,Joan Balcells,Joan Sanchez Del Toledo,Courtney L. Robertson,Dwight Bailey,Lauren Piper,William Tsai,John Ragheb,Rachel S. Agbeko,Nicole F. O’Brien,Amber Young,Neal J. Thomas,Sandra Buttram,Santiago Borasino,JoAnne E Natale,Christopher C. Giza,David Shellington,Deborah M. Stein,Robert S. B. Clark,Alicia Au,Jerry J. Zimmerman,Jose A. Pineda,Peter Ferrazzano +45 more
TL;DR: There were marked differences in medical goals for children with severe traumatic brain injury across the international consortium, and these differences seemed to be greatest in areas with the weakest evidence in the literature.